<DOC>
	<DOCNO>NCT00709722</DOCNO>
	<brief_summary>The aim open multi-center study determine efficient safe dose dose schedule NKT-01 induction response treatment lupus nephritis .</brief_summary>
	<brief_title>Safety Efficacy Deoxyspergualin ( NKT-01 ) Patients With Lupus Nephritis</brief_title>
	<detailed_description>The purpose phase I/II study ia establish dose NKT-01 lead complete response minimum 6 cycle treatment without cause WHO grade 3 leukopenia ( WBC &lt; 2x10^9/L ) . The patient suffer uncontrolled lupus nephritis ( LN ) take OCS ( &lt; = 1.0 mf/kf/day , maximum dose 80 mg/day ) addition NKT-01 . Therefore aim open multi-center study determine efficient safe dose dose schedule NKT-01 induction response treatment lupus nephritis .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Gusperimus</mesh_term>
	<criteria>Males female age 1870 year . A diagnosis SLE accord ACR criterion ( least 4/11 criterion ) . Sufficient sign diagnose active SLE nephritis . Serum creatinine concentration &lt; = 5.0 mg/dL . Leucocyte count &gt; = 4000/uL . Receiving OCS ( &lt; = 1.0 mg/kg/day ; maximum dose 80 mg/day ) . Prior treatment cyclophosphamide , azathioprine , cyclosporin A , immunosuppressive drug . Chronic infection HIV , Hepatitis B , Hepatitis C. Acute infection include fungal , viral , bacterial protozoal disease . Liver toxicity ( WHO CTC class 2 high ) . No adequate liver function ( total bilirubin &gt; 25 umol/L = 1.4 mg/dL unless explain otherwise ( e.g . inherit , hemolysis ) , SGOT &gt; 2.5 x N , SGPT &gt; 2.5 x N ) . Pregnant lactate woman Female patient child bear age without safe method contraception . Anemia ( hemoglobin &lt; 8.0 g/dL ) , leucopenia ( leucocytes &lt; 4000/uL unless attributable SLE : leucocytes &lt; 2000/uL ) , thrombocytopenia ( platelet &lt; 50000/uL ) . Neutrophils 1000/uL . Hypogammaglobulinemia 400 mg/dL serum IgG . Any condition eye investigator might render patient unsuitable participation study . This especially include major active SLE organ involvement kidney . Patients SLE involvement central nervous system allow include study . History malignancy . Current participation another trial lass 6 month since participation similar trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Lupus nephritis</keyword>
	<keyword>Deoxyspergualin</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>